Evaluation of Clinical Efficacy and Immunogenicity of Drug Eritromax at Blau Farmaceutica S.A. Laboratory in Relation to Drug Eprex, Produced by Janssen-Cilag Laboratory in Participants With Secondary Anemia to Chronic Kidney Disease.
Phase of Trial: Phase III
Latest Information Update: 15 Apr 2016
At a glance
- Drugs Epoetin alfa (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 06 Apr 2016 Planned End Date changed from 1 Feb 2016 to 1 Apr 2017, according to ClinicalTrials.gov record.
- 06 Apr 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Jun 2016, according to ClinicalTrials.gov record.